Suppression of Dynamical Network Biomarker Signals at the Predisease State (Mibyou) before Metabolic Syndrome in Mice by a Traditional Japanese Medicine (Kampo Formula) Bofutsushosan

Keiichi Koizumi, Makito Oku, Shusaku Hayashi, Akiko Inujima, Naotoshi Shibahara, Luonan Chen, Yoshiko Igarashi, Kazuyuki Tobe, Shigeru Saito, Makoto Kadowaki, Kazuyuki AiharaEvidence-based 2020 · DOI

TL;DR

This study demonstrates that a traditional Japanese herbal medicine, Bofutsushosan (BTS), can suppress the "predisease" state (Mibyou) of metabolic syndrome in mice. By targeting and stabilizing the fluctuations of specific genes identified by Dynamical Network Biomarker (DNB) theory, BTS appears to prevent the progression to full-blown metabolic syndrome, offering a novel preventive therapeutic strategy.

What Problem Does This Paper Address?

Metabolic syndrome, a cluster of conditions that increase the risk of heart disease, stroke, and diabetes, is a growing global health concern. Current treatments often focus on managing symptoms once the disease has manifested. However, traditional medicine, particularly in Japan and China, emphasizes intervening at an earlier, "predisease" stage, known as "Mibyou." This paper addresses the challenge of scientifically validating such preemptive interventions. Specifically, it builds upon previous work that identified a "predisease" state in a mouse model of metabolic syndrome (TSOD mice) using Dynamical Network Biomarker (DNB) theory, characterized by specific gene expression patterns. The core problem is to determine if a known therapeutic agent, Bofutsushosan (BTS), can effectively prevent or mitigate this identified predisease state.

Methods

The researchers utilized a combination of established and novel approaches. The core methodology involved:

  • Dynamical Network Biomarker (DNB) Theory: This mathematical framework was used to identify early warning signals of critical transitions in complex systems. In this study, it was applied to gene expression data to detect the predisease state in TSOD mice. The DNB theory quantifies fluctuations and correlations among a set of genes (DNB genes) that signal an impending shift to a different state.
  • Microarray Analysis: High-throughput gene expression profiling was performed on TSOD mice treated with BTS and a control group at various time points (3-7 weeks of age). This allowed for the comprehensive analysis of gene expression changes.
  • Statistical Analysis: Standard statistical methods were employed for data preprocessing, including normalization and log-transformation. Differentially Expressed Genes (DEGs) were identified using fold-change filtering and hypothesis testing with Benjamini-Hochberg correction for multiple testing.
  • Clustering Analysis: Hierarchical clustering was used to group genes with similar temporal expression patterns, helping to understand the broader impact of BTS.
  • DNB Score Calculation: Specific DNB scores (average standard deviation and average correlation strength) were calculated to quantitatively assess the impact of BTS on the identified predisease gene network.
  • Network Analysis (STRING Database): Protein-protein interaction networks were analyzed to explore potential functional relationships between DNB genes and DEGs.

Datasets

The study utilized gene expression data generated from TSOD mice. The microarray datasets generated and analyzed during this study are available in the Gene Expression Omnibus (GEO) repository under accession number GSE112653. No new benchmarks were introduced; rather, the study leveraged existing data and established analytical tools.

Key Insights and Ideas

  • Scientific Validation of Mibyou: The study provides the first scientific validation of the concept of intervening in the "Mibyou" (predisease) state, moving beyond empirical observations of traditional medicine.
  • BTS as a Stabilizer: BTS appears to act not by directly altering the average expression of DNB genes, but by suppressing their fluctuations and correlations. This suggests a mechanism of stabilizing the system rather than directly targeting specific disease pathways.
  • Early Intervention is Key: The effectiveness of BTS was observed in suppressing the predisease state before the onset of overt metabolic syndrome, highlighting the potential of preemptive treatment.
  • DNB Theory as a Predictive Tool: The DNB theory proved instrumental in identifying a specific, quantifiable predisease state, which then served as a target for evaluating the therapeutic intervention.

Key Results

  • Suppression of DNB Signals: BTS administration significantly suppressed the early warning signals of the DNB genes at 5 weeks of age and beyond. Specifically, the standard deviations of 134 out of 147 DNB genes decreased at 5 weeks, with 80 showing over a 50% reduction.
  • Reduced Body Weight and Blood Glucose: At 7 weeks of age, BTS-treated mice exhibited significantly lower body weight and blood glucose levels compared to the untreated control group.
  • Limited Impact on Average Gene Expression: While BTS suppressed fluctuations, it did not significantly alter the average expression levels of most DNB genes, suggesting a mechanism focused on stability.
  • Identification of Immune-Related Genes: Network analysis revealed interactions between DNB genes and DEGs, with several immune system-related genes (Gata3, Myc, Cd4, Elane, Il31) identified as potentially important regulators at the predisease state.

Limitations and Future Work

  • Mechanism of Action: While the study demonstrates BTS's effect on DNB scores, the precise molecular mechanisms by which BTS achieves this stabilization remain complex due to the numerous compounds in the Kampo formula.
  • Generalizability: The study was conducted in a mouse model. Further research is needed to confirm these findings in human populations and to explore the efficacy of BTS and other Kampo formulas for Mibyou in various conditions.
  • Broader DNB Applications: The authors suggest that DNB scores can be used to quantify how lifestyle changes (diet, exercise) improve health stability, contributing to preventive therapies. They also aim to clarify the roles of identified immune-related genes in the predisease state and metabolic syndrome, potentially leading to novel therapeutic targets.

Summary updated

Abstract

Due to the increasing incidence of metabolic syndrome, the development of new therapeutic strategies is urgently required. One promising approach is to focus on the predisease state (so-called <i>Mibyou</i> in traditional Japanese medicine) before metabolic syndrome as a preemptive medical target. We recently succeeded in detecting a predisease state before metabolic syndrome using a mathematical theory called the dynamical network biomarker (DNB) theory. The detected predisease state was characterized by 147 DNB genes among a total of 24,217 genes in TSOD (Tsumura-Suzuki Obese Diabetes) mice, a well-accepted model of metabolic syndrome, at 5 weeks of age. The timing of the predisease state was much earlier than the onset of metabolic syndrome in TSOD mice reported to be at approximately 8-12 weeks of age. In the present study, we investigated whether the predisease state in TSOD mice can be inhibited by the oral administration of a Kampo formula, bofutsushosan (BTS), which is usually used to treat obese patients with metabolic syndrome in Japan, from 3 to 7 weeks of age. We found the comprehensive suppression of the early warning signals of the DNB genes by BTS at 5 weeks of age and later. Specifically, the standard deviations of 134 genes among the 147 DNB genes decreased at 5 weeks of age as compared to the nontreatment control group, and 80 of them showed more than 50% reduction. In addition, at 7 weeks of age, the body weight and blood glucose level were significantly lower in the BTS-treated group than in the nontreatment control group. The results of our study suggest a novel mechanism of BTS; it suppressed fluctuations of the DNB genes at the predisease state before metabolic syndrome and thus prevented the subsequent transition to metabolic syndrome. In conclusion, this study demonstrated the preventive and preemptive effects of a Kampo formula on <i>Mibyou</i> before metabolic syndrome for the first time based on scientific evaluation.
BibTeX
@inproceedings{koizumi2020suppression,
  author = {Keiichi Koizumi and Makito Oku and Shusaku Hayashi and Akiko Inujima and Naotoshi Shibahara and Luonan Chen and Yoshiko Igarashi and Kazuyuki Tobe and Shigeru Saito and Makoto Kadowaki and Kazuyuki Aihara},
  title = {{Suppression of Dynamical Network Biomarker Signals at the Predisease State (<i>Mibyou</i>) before Metabolic Syndrome in Mice by a Traditional Japanese Medicine (Kampo Formula) Bofutsushosan}},
  booktitle = {Evidence-based},
  year = {2020},
  doi = {10.1155/2020/9129134},
}
Figure